Lumenis partners with Mandy Moore on DED awareness

Article

The actress and singer-songwriter will serves as the brand ambassador for OptiLight, a new dry eye disease treatment.

Lumenis has launched a partnership with actress and singer-songwriter Mandy Moore as the new brand ambassador for OptiLight, the company’s bright solution for dry eyes. She is featured in a new OptiLight campaign, according to a news release.

OptiLight is the first and only light-based therapy for dry eye disease (DED) that uses a patented optimal pulse technology (OPT). It is designed to help improve DED symptoms with a series of quick, gentle, in-office treatments.

Moore’s partnership with Lumenis comes after she experienced signs and symptoms of DED. She said using OptiLight as treatment significantly improved her condition.

“I’m excited to partner with Lumenis and share how OptiLight has made a real impact on my life. For years, I suffered from dry eye disease, but I didn’t know I had it ... it was a constant frustration on the set and at home with my family,” Moore said, in a statement.

After being diagnosed wtih DED, Moore said receiving treatment from OptiLight allowed her to continue normal life.

"Now, I can focus more time on what’s important to me, rather than battling the constant nuisance and discomfort of dry eye disease, and I want to inspire other people to say, ‘I won’t just live with it,’” she said.

Learn more about OptiLight here

See more dry eye coverage

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
© 2024 MJH Life Sciences

All rights reserved.